Literature DB >> 22634898

High pressure enhances the effect of hyperthermia in intraperitoneal chemotherapy with oxaliplatin: an experimental study.

Olivier Facy1, Sophie Al Samman, Guy Magnin, Francois Ghiringhelli, Sylvain Ladoire, Bruno Chauffert, Patrick Rat, Pablo Ortega-Deballon.   

Abstract

BACKGROUND: Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) achieve good results in selected patients with peritoneal carcinomatosis. High intra-abdominal pressure could enhance the penetration of chemotherapy drugs. The aim of this study was to compare the effects of high pressure and hyperthermia when used separately and when combined in terms of blood and tissue absorption of oxaliplatin in a swine model of intraperitoneal chemotherapy.
METHODS: Four groups of 5 pigs each underwent laparotomy and open intraperitoneal chemotherapy with oxaliplatin at a constant concentration (150 mg/L) for 30 minutes in normothermia and atmospheric pressure (group 1), or hyperthermia (42°C) and atmospheric pressure (group 2), or normothermia and high pressure (25 cm H2O) (group 3), or hyperthermia and high pressure (group 4). High pressure was achieved thorough a water column over the abdomen. Systemic absorption and abdominal tissue mapping of the penetration of oxaliplatin in each group were studied.
RESULTS: Blood concentrations of oxaliplatin were similar in the different groups. Hyperthermia achieved higher concentrations in visceral surfaces (P = 0.0014), but not in parietal surfaces. High pressure enhanced diffusion of the drug in both the visceral and parietal peritoneum (P = 0.0058 and P = 0.0044, respectively). The combination of hyperthermia and high pressure significantly increased the penetration of oxaliplatin and achieved the highest tissue concentrations (10.39 mg/kg vs 5.48 mg/kg; P = 0.00001 in the visceral peritoneum, and 66.16 mg/kg vs 35.62 mg/kg; P = 0.0003 in the parietal peritoneum).
CONCLUSIONS: Open high-pressure HIPEC with oxaliplatin is feasible in the pig. Hyperthermia enhances diffusion in the visceral peritoneum, whereas high pressure is effective in the visceral and parietal peritoneum. The combination of the two achieves the highest tissue concentrations of oxaliplatin.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22634898     DOI: 10.1097/SLA.0b013e3182582b38

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  22 in total

Review 1.  Severe peritoneal sclerosis after repeated pressurized intraperitoneal aerosol chemotherapy with oxaliplatin (PIPAC OX): report of two cases and literature survey.

Authors:  M Graversen; S Detlefsen; P Pfeiffer; L Lundell; M B Mortensen
Journal:  Clin Exp Metastasis       Date:  2018-04-28       Impact factor: 5.150

2.  Laparoscopic HIPEC: A bridge between open and closed-techniques.

Authors:  Marco Lotti; Michela Giulii Capponi; Dario Piazzalunga; Elia Poiasina; Michele Pisano; Roberto Manfredi; Luca Ansaloni
Journal:  J Minim Access Surg       Date:  2016 Jan-Mar       Impact factor: 1.407

Review 3.  Hyperthermic intraperitoneal chemotherapy with oxaliplatin for peritoneal carcinomatosis: a clinical pharmacological perspective on a surgical procedure.

Authors:  Loek A W de Jong; Fortuné M K Elekonawo; Philip R de Reuver; Andre J A Bremers; Johannes H W de Wilt; Frank G A Jansman; Rob Ter Heine; Nielka P van Erp
Journal:  Br J Clin Pharmacol       Date:  2018-10-25       Impact factor: 4.335

Review 4.  Pressurized intraperitoneal aerosol chemotherapy and its effect on gastric-cancer-derived peritoneal metastases: an overview.

Authors:  Miguel Alberto; Andreas Brandl; Pankaj Kumar Garg; Safak Gül-Klein; Mathias Dahlmann; Ulrike Stein; Beate Rau
Journal:  Clin Exp Metastasis       Date:  2019-02-04       Impact factor: 5.150

5.  Scintigraphic peritoneography reveals a non-uniform 99mTc-Pertechnetat aerosol distribution pattern for Pressurized Intra-Peritoneal Aerosol Chemotherapy (PIPAC) in a swine model.

Authors:  Alexander Bellendorf; Veria Khosrawipour; Tanja Khosrawipour; Simon Siebigteroth; Joseph Cohnen; David Diaz-Carballo; Andreas Bockisch; Jürgen Zieren; Urs Giger-Pabst
Journal:  Surg Endosc       Date:  2017-06-22       Impact factor: 4.584

Review 6.  Is PIPAC a Treatment Option in Upper and Lower Gastrointestinal Cancer with Peritoneal Metastasis?

Authors:  Safak Guel-Klein; Miguel Enrique Alberto Vilchez; Wim Ceelen; Beate Rau; Andreas Brandl
Journal:  Visc Med       Date:  2022-03-21

7.  A minimally invasive approach for peritonectomy procedures and hyperthermic intraperitoneal chemotherapy (HIPEC) in limited peritoneal carcinomatosis: The American Society of Peritoneal Surface Malignancies (ASPSM) multi-institution analysis.

Authors:  A Arjona-Sanchez; J Esquivel; O Glehen; G Passot; K K Turaga; D Labow; S Rufian-Peña; R Morales; K van der Speeten
Journal:  Surg Endosc       Date:  2018-07-12       Impact factor: 4.584

8.  Cytoreductive Surgery and Intraperitoneal Hyperthermic Chemotherapy (HIPEC) by Minimally Invasive Approach, an Initial Experience.

Authors:  A Arjona-Sanchez; S Rufian-Peña; J M Sanchez-Hidalgo; A Casado-Adam; A Cosano-Alvarez; J Briceño-Delgado
Journal:  World J Surg       Date:  2018-10       Impact factor: 3.352

9.  Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) with Low-Dose Cisplatin and Doxorubicin in Gastric Peritoneal Metastasis.

Authors:  Giorgi Nadiradze; Urs Giger-Pabst; Juergen Zieren; Dirk Strumberg; Wiebke Solass; Marc-André Reymond
Journal:  J Gastrointest Surg       Date:  2015-10-28       Impact factor: 3.452

10.  Inflammatory Response and Toxicity After Pressurized IntraPeritoneal Aerosol Chemotherapy.

Authors:  Hugo Teixeira Farinha; Fabian Grass; Ismaïl Labgaa; Basile Pache; Nicolas Demartines; Martin Hübner
Journal:  J Cancer       Date:  2018-01-01       Impact factor: 4.207

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.